References
- Toivola RJ, Karjalainen AJ, Kurkela KA, Soderwall ML, Kangas LM, Blanco GL, Sunduiqst HK. Novel tri-phenyl alkane and alkene derivatives and their preparation and use. U.S. Patent 4,696,949:1987.
- Charles MB, Norma LB, Kevin JE, Juanelle LL, Jessica DP, Michael GR, Michael FW. Solubilization and dissolution of tamoxifen-hydroxybutenyl cyclodextrin complexes. J Pharm Sci 2006;95:2246–2255.
- Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 2006;147 Suppl 1:S269–S276.
- Buddhadev L, Biswajit M.Tamoxifen citrate encapsulated sustained release liposomes: preparation and evaluation of physicochemical properties. Sci Pharm 2010;78(3):507–515.
- Jayanta KS, Rita M, Saibal KB, Ranadeep M, Angshuman B. Controlled release of tamoxifen citrate encapsulated in cross-linked guar gum nanoparticles. Int J Biol Macromol 2011;49(3):390–396.
- Torne SJ, Ansari KA, Vavia PR, Trotta F, Cavalli R. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Deliv 2010;17:419–425.
- Trotta F, Tumiatti W. Cross-linked polymers based on cyclodextrins for removing polluting agents. U.S. Patent 10/510,792:2002.
- Ansari KA, Vavia PR, Trotta F, Cavalli R. Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech 2011;12:279–286.
- Cavalli R, Trotta F, Tumiatti W. Cyclodextrin-based nanosponges for drug delivery. J Incl Phenom Macro 2006;56:209–213.
- Swaminathan S, Vavia PR, Trotta F, Torne SJ. Formulation of β cyclodextrin based nanosponges of itraconazole. J Incl Phenom Macro 2007;57:89–94.
- Swaminathan S, Pastero L, Serpe L, Trotta F, Vavia P, Aquilano D et al. Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm 2010;74:193–201.
- MacCallum J, Cummings J, Dixon JM, Miller WR. Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma. J Chromatogr B, Biomed Appl 1996;678:317–323.
- Cavalli R, Peira E, Caputo O, Gasco MR. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrins. Int J Pharm 1999;182:59–69.
- Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D et al.; European Federation of Pharmaceutical Industries Association and European Centre for the Validation of Alternative Methods. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 2001;21:15–23.
- Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997;40 Suppl:S13–S19.
- Van Asperen J, Van Tellingen O, Beijnen JH. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 1998;37:429–435.
- Meerum Terwogt JM, Malingré MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 1999;5:3379–3384.
- Oda M, Saitoh H, Kobayashi M, Aungst BJ. β-cyclodextrin as a suitable solubilizing agent for in situ absorption study of poorly water-soluble drugs. Int J Pharm 2004;280:95–102.
- Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6 α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994;54:5543–5546.